神经分泌生物科学(NBIX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NBIX 神经分泌生物科学

休市中 08-23 16:00:00 EDT

152.81

+0.24

+0.16%

盘后152.81

+0.000.00%

19:47 EDT

最高154.87	最低151.71	成交量52.78万
今开153.00	昨收152.57	日振幅2.07%
总市值154.30亿	流通市值152.47亿	总股本1.01亿
成交额8,080万	换手率0.53%	流通股本9,977万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"NBIX","market":"US","secType":"STK","nameCN":"神经分泌生物科学","latestPrice":152.81,"timestamp":1724443200000,"preClose":152.57,"halted":0,"volume":527833,"hourTrading":{"tag":"盘后","latestPrice":152.81,"preClose":152.81,"latestTime":"19:47 EDT","volume":13751,"amount":2101283.93,"timestamp":1724456857159},"delay":0,"floatShares":99774823,"shares":100976249,"eps":3.29309,"marketStatus":"休市中","marketStatusCode":7,"change":0.24,"latestTime":"08-23 16:00:00 EDT","open":153,"high":154.865,"low":151.71,"amount":80800443.39347999,"amplitude":0.020679,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":3.29309,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1724659200000},"adr":0,"listingDate":832824000000,"adjPreClose":152.57,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":152.58,"preClose":152.57,"latestTime":"08:48 EDT","volume":17,"amount":2593.86,"timestamp":1724417321308},"postHourTrading":{"tag":"盘后","latestPrice":152.81,"preClose":152.81,"latestTime":"19:47 EDT","volume":13751,"amount":2101283.93,"timestamp":1724456857159},"volumeRatio":0.7372743619310173,"impliedVol":0.6187,"impliedVolPercentile":0.9206},"requestUrl":"/m/hq/s/NBIX/tweets","defaultTab":"tweets","newsList":[{"id":"2458154745","title":"神经分泌生物科学2024财年第二财季实现净利润65.00百万美元，同比减少31.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2458154745","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458154745?lang=zh_cn&edition=full","pubTime":"2024-08-10 00:16","pubTimestamp":1723220217,"startTime":"0","endTime":"0","summary":"8月10日，神经分泌生物科学公布财报，公告显示公司2024财年第二财季净利润为65.00百万美元，同比减少31.94%；其中营业收入为5.90亿美元，同比增加30.24%，每股基本收益为0.64美元。从资产负债表来看，神经分泌生物科学总负债7.96亿美元，其中短期债务35.40百万美元，资产负债比为4.16，流动比率为4.19。机构评级：截至2024年8月10日，当前有24家机构对神经分泌生物科学目标价做出预测，其中目标均价为171.67美元，其中最低目标价为131.00美元，最高目标价为219.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240810001702958c4a27&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240810001702958c4a27&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NBIX"],"gpt_icon":0},{"id":"2456231070","title":"奥本海默：维持Neurocrine Biosciences(NBIX.US)评级，由优于大市调整至优于大市评级, 目标价由216.","url":"https://stock-news.laohu8.com/highlight/detail?id=2456231070","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456231070?lang=zh_cn&edition=full","pubTime":"2024-08-03 23:52","pubTimestamp":1722700351,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0823416689.USD","LU0320765992.SGD","LU2065171402.SGD","NBIX","LU2065170008.USD","LU2065169927.USD","LU2324357040.USD","BK4139","LU0889565916.HKD","LU2065171311.SGD","LU0109394709.USD"],"gpt_icon":0},{"id":"1197596591","title":"异动解读 | 神经分泌生物科学公司业绩超预期 股价大涨10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1197596591","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197596591?lang=zh_cn&edition=full","pubTime":"2024-08-01 21:38","pubTimestamp":1722519505,"startTime":"0","endTime":"0","summary":"神经分泌生物科学公司今日盘中大涨10.57%,报收于150美元左右,引发市场广泛关注。公司此前公布的第二季度业绩显示,总销售额达5.902亿美元,其中神经系统药物Ingrezza的净销售额高达5.838亿美元,均超过了分析师的预期。公司同时上调了Ingrezza全年销售预期,从之前的21亿-22亿美元上调至22.5亿-23亿美元。分析人士表示,作为公司主打产品,Ingrezza未来的销售表现将是决定公司股价走势的关键因素。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBIX"],"gpt_icon":0},{"id":"2456386384","title":"神经分泌生物科学盘中异动 快速拉升8.95%报154.25美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2456386384","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456386384?lang=zh_cn&edition=full","pubTime":"2024-08-01 21:31","pubTimestamp":1722519110,"startTime":"0","endTime":"0","summary":"北京时间2024年08月01日21时31分，神经分泌生物科学股票出现异动，股价大幅上涨8.95%。截至发稿，该股报154.25美元/股，成交量13.2135万股，换手率0.13%，振幅3.53%。神经分泌生物科学股票所在的制药行业中，整体涨幅为1.91%。该公司推动中枢神经系统和内分泌相关类别的候选药物的发展。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408012131509574d764&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408012131509574d764&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2324357040.USD","LU0109394709.USD","LU0889565916.HKD","LU2065170008.USD","NBIX","LU0320765992.SGD","LU0823416689.USD","LU2065171402.SGD","LU2065171311.SGD","LU2065169927.USD","BK4139"],"gpt_icon":0},{"id":"1171209139","title":"异动解读 | 神经分泌生物科学公司业绩超预期 盘前大涨近9%","url":"https://stock-news.laohu8.com/highlight/detail?id=1171209139","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1171209139?lang=zh_cn&edition=full","pubTime":"2024-08-01 20:56","pubTimestamp":1722516977,"startTime":"0","endTime":"0","summary":"神经分泌生物科学公司(Neurocrine Biosciences,股票代码NBIX)今日盘前大涨8.78%,报收于150美元左右,引发市场广泛关注。\n\n公司此前公布的第二季度业绩显示,总销售额达5.902亿美元,其中神经系统药物Ingrezza的净销售额高达5.838亿美元,均超过了分析师的预期。公司同时上调了Ingrezza全年销售预期,从之前的21亿-22亿美元上调至22.5亿-23亿美元。\n\n第二季度业绩和销售预期的双双超预期,无疑增强了市场对该公司长期增长前景的信心,推动了公司股价的大涨。分析人士表示,作为公司主打产品,Ingrezza未来的销售表现将是决定公司股价走势的关键因素。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBIX"],"gpt_icon":0},{"id":"2456485075","title":"BUZZ-Neurocrine 第二季度业绩增长，上调神经系统药物全年销售预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2456485075","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456485075?lang=zh_cn&edition=full","pubTime":"2024-08-01 20:00","pubTimestamp":1722513617,"startTime":"0","endTime":"0","summary":"    8月1日 - ** 制药商Neurocrine Biosciences  股价盘前上涨约6%至150美元** 该公司公布的  第二季度业绩高于华尔街预期，并上调了其神经药物 Ingrezza 的年度净销售额预期** NBIX 季度总销售额为 5.902 亿美元，其中 Ingrezza 的净销售额为 5.838 亿美元。** 分析师平均预计营业额为 5.46 亿美元，Ingrezza 的销售额为 5.4086 亿美元--LSEG 数据** 公司认为Ingrezza的年销售额在22.5亿-23亿美元之间，而之前的预期为21亿-22亿美元，分析师的预期为21.8亿美元。第二季度每股收益为 1.63 美元，分析师预期为 1.03 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065171311.SGD","BK4139","NBIX","LU2065171402.SGD","LU0823416689.USD","LU2065169927.USD","BUZZ","LU2065170008.USD","LU2324357040.USD","LU0109394709.USD","LU0889565916.HKD","LU0320765992.SGD"],"gpt_icon":0},{"id":"2455968713","title":"Neurocrine Biosciences Inc   预计每股收益1.03美元 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2455968713","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2455968713?lang=zh_cn&edition=full","pubTime":"2024-07-31 00:57","pubTimestamp":1722358640,"startTime":"0","endTime":"0","summary":"   * Neurocrine Biosciences Inc     8月1日公布的截至2024年6月30日的财报显示，该公司的季度收入预计将有所增长。* 根据LSEG的数据，24位分析师的平均预期显示，这家总部位于加利福尼亚州圣迭戈的公司的营收将从去年同期的4.527亿美元增至5.4707亿美元，增幅为20.8%。* LSEG 分析师对 Neurocrine Biosciences Inc 的平均预期为每股收益 1.03 美元。* 华尔街对 Neurocrine Biosciences Inc 的 12 个月目标价中位数为 160.13 美元，高于其上次收盘价 145.25 美元。7月30日 - 上一季度业绩。除非另有说明，所有数字均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBIX"],"gpt_icon":0},{"id":"2452858464","title":"神经分泌生物科学推出Ingrezza® Sprinkle（Valbenazine）胶囊以简化经历吞咽困难的患者的用药。","url":"https://stock-news.laohu8.com/highlight/detail?id=2452858464","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2452858464?lang=zh_cn&edition=full","pubTime":"2024-07-18 20:30","pubTimestamp":1721305847,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0320765992.SGD","LU0889565916.HKD","LU2324357040.USD","NBIX","LU2065171402.SGD","LU2065171311.SGD","LU2065169927.USD","LU0109394709.USD","BK4139","LU2065170008.USD"],"gpt_icon":0},{"id":"2450884816","title":"小摩：维持Neurocrine Biosciences(NBIX.US)评级，由增持调整至增持评级, 目标价由169.00美元调整至173.","url":"https://stock-news.laohu8.com/highlight/detail?id=2450884816","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2450884816?lang=zh_cn&edition=full","pubTime":"2024-07-11 00:37","pubTimestamp":1720629443,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00B3S45H60.SGD","BK4581","IE0034235188.USD","LU1914381329.SGD","IE00B775SV38.USD","LU0267386448.USD","IE00BJTD4V19.USD","LU1084165304.USD","BK4588","LU1496350171.SGD","LU1119994496.HKD","BK4504","LU0496365809.HKD","LU0211328371.USD","LU1244550221.USD","LU0070302665.USD","LU0149725797.USD","BK4533","LU0417517546.SGD","LU0976567544.SGD","LU1894683264.USD","LU1363072403.SGD","IE000M9KFDE8.USD","LU0310799852.SGD","LU1244550494.USD","LU1894683348.USD","LU0211327993.USD","LU1670628061.USD","BK4566","IE00BHPRN162.USD","IE00BLSP4452.SGD","LU1032466523.USD","IE00B1XK9C88.USD","BK4139","BK4550","LU0234572021.USD","LU0238689110.USD","LU1162221912.USD","IE00BZ1G4Q59.USD","LU2324357040.USD","LU2065169927.USD","NBIX","LU1668664300.SGD","LU1496350502.SGD","LU2065171402.SGD","IE00BFXG1179.USD","IE00BJTD4N35.SGD","LU0211331839.USD","LU0256863811.USD","IE00BWXC8680.SGD"],"gpt_icon":0},{"id":"2450385481","title":"美国研究综述-Nvidia、高通、特斯拉","url":"https://stock-news.laohu8.com/highlight/detail?id=2450385481","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2450385481?lang=zh_cn&edition=full","pubTime":"2024-07-10 15:41","pubTimestamp":1720597288,"startTime":"0","endTime":"0","summary":"    路透7月10日 - 华尔街证券分析师周三调整了对几家美国上市公司的评级和目标价，其中包括Nvidia、高通和特斯拉。* Nvidia Corp   ：KeyBanc将目标价上调至180美元 * 高通公司   ：KeyBanc将目标价上调至225美元  * 特斯拉  ：汇丰银行将目标价从120美元上调至130美元  以下是路透周三报道的美国公司研究报告摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LZ","QCOM","RGA","LU2237443382.USD","MPWR","NICE","SAIC","BK4177","NVDA","SAGE","TWLO","GL","NBIX","IE0004445015.USD","MOH","CACI","SG9999014575.USD","CRUS","TSLA","EQH","AMD","RCUS","PFG","MU","CNO","AFL","BK4550","ENLC","KO","TSLL","KDP","BHF","PRI","PRU","JXN","DNLI","MRVL","SG9999015986.USD","CNC","LDOS","LU1169590202.USD","BK4559","ON","DVN","FIVN","BAH","LGIH","LU2237443549.SGD","RNG","AMP"],"gpt_icon":1},{"id":"2448966539","title":"神经分泌生物科学宣布美国FDA接受新药申请并为儿童和成人CAH患者授予Crinecerfont优先审评。","url":"https://stock-news.laohu8.com/highlight/detail?id=2448966539","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2448966539?lang=zh_cn&edition=full","pubTime":"2024-07-01 19:30","pubTimestamp":1719833402,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0211327993.USD","LU0889565916.HKD","LU1267930490.SGD","LU0792757196.USD","LU2065169927.USD","LU1267930813.SGD","LU2065171311.SGD","LU0320765992.SGD","LU0889566641.SGD","LU0310799852.SGD","SG9999001440.SGD","BK4588","CAH","BK4585","LU0052756011.USD","LU0310800965.SGD","BK4139","LU0128525689.USD","NBIX","LU0109394709.USD","LU2065171402.SGD","BK4175","LU1267930227.SGD","LU0006061336.USD","LU0211328371.USD","LU1571399168.USD","LU2065170008.USD"],"gpt_icon":0},{"id":"2441454257","title":"神经分泌生物科学盘中异动 股价大跌5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2441454257","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2441454257?lang=zh_cn&edition=full","pubTime":"2024-06-05 03:56","pubTimestamp":1717531001,"startTime":"0","endTime":"0","summary":"北京时间2024年06月05日03时56分，神经分泌生物科学股票出现波动，股价快速下跌5.06%。截至发稿，该股报132.84美元/股，成交量90.0722万股，换手率0.90%，振幅4.67%。神经分泌生物科学股票所在的制药行业中，整体涨幅为0.29%。神经分泌生物科学公司简介：Neurocrine Biosciences Inc 是一家研究型制药公司。该公司推动中枢神经系统和内分泌相关类别的候选药物的发展。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240605035641af8bf2d9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240605035641af8bf2d9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2065171311.SGD","LU2065169927.USD","LU0109394709.USD","LU2065171402.SGD","NBIX","LU0889565916.HKD","LU2065170008.USD","BK4139","LU0320765992.SGD"],"gpt_icon":0},{"id":"2440946133","title":"神经分泌生物科学宣布克林塞芬洛用于治疗新英格兰医学杂志成人第三期Cah主要催化剂™研究结果的出版","url":"https://stock-news.laohu8.com/highlight/detail?id=2440946133","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2440946133?lang=zh_cn&edition=full","pubTime":"2024-06-03 19:30","pubTimestamp":1717414206,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2065171402.SGD","LU2065169927.USD","BK4139","LU0320765992.SGD","NBIX","LU2065171311.SGD","LU0109394709.USD","LU2065170008.USD","LU0889565916.HKD"],"gpt_icon":0},{"id":"2439202115","title":"神经分泌生物科学盘中异动 急速下挫5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2439202115","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2439202115?lang=zh_cn&edition=full","pubTime":"2024-05-29 21:39","pubTimestamp":1716989968,"startTime":"0","endTime":"0","summary":"北京时间2024年05月29日21时39分，神经分泌生物科学股票出现波动，股价急速下挫5.07%。神经分泌生物科学股票所在的制药行业中，整体跌幅为0.10%。神经分泌生物科学公司简介：Neurocrine Biosciences Inc 是一家研究型制药公司。该公司推动中枢神经系统和内分泌相关类别的候选药物的发展。消息层面，截至21时39分，《瑞银：维持Neurocrine Biosciences评级，由买入调整至买入评级, 目标价由174.00美元调整至193.00美元。》资讯为影响神经分泌生物科学的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240529213928941eae4e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240529213928941eae4e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0109394709.USD","LU2065171311.SGD","LU2065171402.SGD","LU2065170008.USD","BK4139","LU2065169927.USD","LU0889565916.HKD","LU0320765992.SGD","NBIX"],"gpt_icon":0},{"id":"2439778538","title":"更新版 1-Neurocrine 公司创始人兼首席执行官戈尔曼将于 10 月退休","url":"https://stock-news.laohu8.com/highlight/detail?id=2439778538","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2439778538?lang=zh_cn&edition=full","pubTime":"2024-05-29 04:33","pubTimestamp":1716928411,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 )) (添加第2-4段中的详细信息)    路透5月28日 - Neurocrine Biosciences    首席执行官凯文-戈尔曼（Kevin Gorman）将于10月11日退休，在他创建公司三十年后，他将由凯尔-加诺（Kyle Gano）接任。Gorman于1992年创立了Neurocrine公司，在2008年被任命为首席执行官之前曾担任过多个领导职务。 凯尔-加诺现任首席业务发展和战略官。收盘后，该公司股价下跌3.2%，报136美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065169927.USD","NBIX","LU0889565916.HKD","LU2065171402.SGD","LU2065171311.SGD","LU0109394709.USD","LU2065170008.USD","BK4139","LU0320765992.SGD"],"gpt_icon":0},{"id":"2439753387","title":"神经分泌生物科学宣布首席执行官继任计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2439753387","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2439753387?lang=zh_cn&edition=full","pubTime":"2024-05-29 04:27","pubTimestamp":1716928036,"startTime":"0","endTime":"0","summary":"神经分泌生物科学宣布首席执行官继任计划","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405290427239efba1f8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405290427239efba1f8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LU2065170008.USD","LU2065171311.SGD","LU2065171402.SGD","NBIX","LU0109394709.USD","LU2065169927.USD","LU0320765992.SGD","LU0889565916.HKD"],"gpt_icon":0},{"id":"2439808533","title":"Neurocrine Biosciences Inc：任命首席业务发展和战略官凯尔·加诺博士为当选首席执行官","url":"https://stock-news.laohu8.com/highlight/detail?id=2439808533","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2439808533?lang=zh_cn&edition=full","pubTime":"2024-05-29 04:26","pubTimestamp":1716927983,"startTime":"0","endTime":"0","summary":"Neurocrine Biosciences Inc：任命首席业务发展和战略官凯尔·加诺博士为当选首席执行官","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024052904262795710d6d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024052904262795710d6d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2065171311.SGD","LU2065171402.SGD","LU0889565916.HKD","LU0320765992.SGD","BK4139","NBIX","LU2065170008.USD","LU2065169927.USD","LU0109394709.USD"],"gpt_icon":0},{"id":"2439538524","title":"Neurocrine 首席执行官即将退休","url":"https://stock-news.laohu8.com/highlight/detail?id=2439538524","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2439538524?lang=zh_cn&edition=full","pubTime":"2024-05-29 04:25","pubTimestamp":1716927905,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透5月28日 - Neurocrine Biosciences   周二表示，凯文-戈尔曼（Kevin Gorman）将于10月11日卸任首席执行官一职，凯尔-加诺（Kyle Gano）将接替他的职务。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","LU2065171311.SGD","LU0889565916.HKD","NBIX","LU2065169927.USD","LU0320765992.SGD","LU2065171402.SGD","BK4139","LU2065170008.USD"],"gpt_icon":0},{"id":"2439758028","title":"神经分泌生物科学宣布首席执行官继任计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2439758028","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2439758028?lang=zh_cn&edition=full","pubTime":"2024-05-29 04:14","pubTimestamp":1716927243,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4139","LU2065170008.USD","LU2065171311.SGD","LU2065171402.SGD","NBIX","LU0109394709.USD","LU2065169927.USD","LU0320765992.SGD","LU0889565916.HKD"],"gpt_icon":0},{"id":"2438754313","title":"瑞银：维持Neurocrine Biosciences(NBIX.US)评级，由买入调整至买入评级, 目标价由174.00美元调整至193.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2438754313","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2438754313?lang=zh_cn&edition=full","pubTime":"2024-05-28 20:17","pubTimestamp":1716898644,"startTime":"0","endTime":"0","summary":"瑞银：维持Neurocrine Biosciences(NBIX.US)评级，由买入调整至买入评级, 目标价由174.00美元调整至193.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405282017279ef94b66&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405282017279ef94b66&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NBIX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.neurocrine.com","stockEarnings":[{"period":"1week","weight":0.0538},{"period":"1month","weight":0.0475},{"period":"3month","weight":0.0962},{"period":"6month","weight":0.1388},{"period":"1year","weight":0.4272},{"period":"ytd","weight":0.1598}],"compareEarnings":[{"period":"1week","weight":0.0141},{"period":"1month","weight":0.0386},{"period":"3month","weight":0.0617},{"period":"6month","weight":0.1069},{"period":"1year","weight":0.2867},{"period":"ytd","weight":0.1827}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Neurocrine Biosciences, Inc.于1992年1月在加利福尼亚州注册成立，并于1996年5月在特拉华州重新注册成立。该公司是一家专注于神经科学的生物制药公司，目的很简单：为有巨大需求的人减轻痛苦，但选择很少。三十年来，该公司运用对神经科学以及大脑和身体系统之间相互联系的独特见解，推进用于治疗未得到充分解决的神经、神经内分泌和神经精神疾病的药物，他们将继续不懈地追求药物，以减轻令人衰弱的疾病和紊乱的负担。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.066296},{"month":2,"riseRate":0.321429,"avgChangeRate":-0.00768},{"month":3,"riseRate":0.428571,"avgChangeRate":-0.006842},{"month":4,"riseRate":0.357143,"avgChangeRate":-0.012064},{"month":5,"riseRate":0.571429,"avgChangeRate":0.045557},{"month":6,"riseRate":0.517241,"avgChangeRate":0.019417},{"month":7,"riseRate":0.482759,"avgChangeRate":-0.002747},{"month":8,"riseRate":0.551724,"avgChangeRate":0.026783},{"month":9,"riseRate":0.571429,"avgChangeRate":0.032175},{"month":10,"riseRate":0.535714,"avgChangeRate":0.029555},{"month":11,"riseRate":0.571429,"avgChangeRate":0.038168},{"month":12,"riseRate":0.642857,"avgChangeRate":0.042544}],"exchange":"NASDAQ","name":"神经分泌生物科学","nameEN":"Neurocrine Biosciences"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"神经分泌生物科学(NBIX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供神经分泌生物科学(NBIX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"神经分泌生物科学,NBIX,神经分泌生物科学股票,神经分泌生物科学股票老虎,神经分泌生物科学股票老虎国际,神经分泌生物科学行情,神经分泌生物科学股票行情,神经分泌生物科学股价,神经分泌生物科学股市,神经分泌生物科学股票价格,神经分泌生物科学股票交易,神经分泌生物科学股票购买,神经分泌生物科学股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"神经分泌生物科学(NBIX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供神经分泌生物科学(NBIX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}